



## UvA-DARE (Digital Academic Repository)

### Studies on the efficacy and toxicity of highly active antiretroviral therapy

Wit, F.W.N.M.

**Publication date**  
2002

[Link to publication](#)

#### **Citation for published version (APA):**

Wit, F. W. N. M. (2002). *Studies on the efficacy and toxicity of highly active antiretroviral therapy*. [Thesis, fully internal, Universiteit van Amsterdam].

#### **General rights**

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

#### **Disclaimer/Complaints regulations**

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

## List of publications

1. Wit FWNM, van Rij RP, Weverling GJ, Lange JMA, Schuitemaker H. **CCR5  $\Delta$ 32 and CCR2 64I polymorphisms do not influence the virological and immunological response to antiretroviral combination therapy.** *Submitted for publication.*
2. Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. **Incidence of and risk factors for severe hepatotoxicity of antiretroviral combination therapy.** *Submitted for publication.*
3. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FWNM, Ledergerber B, Lundgren JD, Furrer H, for seven European HIV cohorts. **Safe interruption of maintenance therapy against prior infection with four common HIV-associated opportunistic pathogens during highly active antiretroviral therapy.** *Submitted for publication.*
4. ADHOC International Steering Committee. **A randomised placebo controlled trial of adefovir dipivoxil in advanced HIV infection.** *Submitted for publication.*
5. Dieleman J, Sturkenboom M, Wit FWNM, Jambroes M, Mulder JW, ten Veen J, Juttmann J, Stricker B, Lange J, van der Ende M. **Low risk of treatment failure one year after substituting nevirapine for human immunodeficiency virus (HIV)-protease inhibitors among HIV-infected patients with viral suppression in a real life setting. The ATHENA cohort.** *Submitted for publication.*
6. Hazenberg M, Otto SA, van Baarle A, Kostense S, Wit FWNM, Lange JMA, Hamann D, Miedema F. **Discordant Responses during antiretroviral therapy: role for immune activation and T-cell redistribution.** *AIDS, in press.*
7. van Praag ME, Wit FWNM, Jurriaans S, de Wolf F, Prins JM, Lange JMA. **Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared to standard of care antiretroviral therapy.** *AIDS, in press.*
8. Wit FWNM, Wood R, Horban A, Beniowski M, Schmidt RE, Gray G, Lazzarin A, Lafeuillade A, Paes D, Carlier H, van Weert L, de Vries C, van Leeuwen R, Lange JMA. **Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.** *AIDS 2001; 15: 2423-2429.*

## List of publications

9. van der Valk M, Gisolf EH, Reiss P, Wit FWNM, Japour A, Weverling GJ et al. **Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.** *AIDS* 2001; **15**: 847-855.
10. Reijers MH, Weverling GJ, Jurriaans S, Roos MT, Wit FWNM, Weigel HM, Ten Kate RW, Mulder JW, Richter C, Ter Hofstede HJ, Sprenger H, Hoetelmans RM, Schuitemaker H, Lange JM. **The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.** *AIDS*. 2001 Jan 5; **15**(1):129-31.
11. den Brinker M, Wit FWNM, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. **Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.** *AIDS*. 2000 Dec 22; **14**(18):2895-902.
12. Wit FWNM. **Experience with nevirapine in previously treated HIV-1-infected individuals.** Dutch HIV-treating physicians. *Antivir Ther*. 2000 Dec; **5**(4):257-66.
13. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FWNM, Reiss P, Lange JM, Kwakkelstein MO, Beijnen JH, Hoetelmans RM. **Nevirapine plus didanosine: once or twice daily combination?** *J Acquir Immune Defic Syndr*. 2000 Sep 1; **25**(1):93-5.
14. Clark DR, Repping S, Pakker NG, Prins JM, Notermans DW, Wit FWNM, Reiss P, Danner SA, Coutinho RA, Lange JM, Miedema F. **T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy.** *Blood*. 2000 Jul 1; **96**(1):242-9.
15. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FWNM, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM. **The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.** *AIDS*. 2000 May 26; **14**(8):F77-82.
16. Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FWNM, Hamann D, van der Ende ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F. **Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy.** INCAS Study Group. *AIDS*. 1999 Feb 4; **13**(2):203-12.

17. Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM. **Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.** *J Infect Dis.* 1999 Apr;179(4):790-8.
18. Reijers MH, Weverling GJ, Jurriaans S, Wit FWNM, van Leeuwen R, Bruisten SM, Frissen PH, Weigel HM, Mulder JW, ten Kate RW, de Wolf F, Schuitemaker H, Lange JM. **[Amsterdam duration of antiretroviral medication (ADAM)-study: induction-suppression treatment in HIV-I infection, preliminary results].** *Ned Tijdschr Geneeskd.* 1998 Oct 3;142(40):2230.
19. Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, Wit FWNM, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH, Lange JM. **The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.** *AIDS.* 1998 Jul 30;12(11):F111-5.
20. Reijers MH, Weverling GJ, Jurriaans S, Wit FWNM, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM. **Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.** *Lancet.* 1998 Jul 18;352(9123):185-90.
21. Wit FWNM, Sol CJ, Renwick N, Roos MT, Pals ST, van Leeuwen R, Goudsmit J, Reiss P. **Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpesvirus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy.** *AIDS.* 1998 Jan 22;12(2):218-9.
22. Kuijper EJ, Wit FWNM, Veenstra J, Bottger EC. **Recovery of *Mycobacterium haemophilum* skin infection in an HIV-1 infected patient after the start of antiretroviral triple therapy.** *Clinical Microbiology and Infection.* 1997 Oct;3(5):584-5.

